SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis…
Press Release
SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference
SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference Paris, January 6…
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer…
SparingVision to Present at Upcoming Investor Conferences
SparingVision to Present at Upcoming Investor Conferences Paris, December 3, 2021 – SparingVision (or the…
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Cambridge, MA, and Paris, France– October 13, 2021 Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading…
SparingVision Conference Participation in H2 2021
SparingVision announces the scientific and investor conferences that its management team will be participating in…
SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting
SparingVision is pleased to announce that it will present a poster highlighting the Company’s recent…
SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SparingVision is pleased to announce that it has presented three posters highlighting the Company’s recent…
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis…
SparingVision Announces Upcoming Poster Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP)…